Nominations for Active and International membership, 2022

Nominations for 2022 membership may be submitted through October 4, 2021, 11:59 pm Eastern. Proposers and supporters of nominations should review the guide below carefully. Questions regarding nominations should be sent by email to staff@the-asci.org.

  • Nomination guide for Active and International membership (PDF). This document should be reviewed for details about the process and to ensure a complete nomination. Note: As of the 2021 cycle, a separate nomination form was eliminated, in favor of an interactive web-based process.
  • Membership nomination support template (for use by Seconders and General Supporters; Word document). This document provides a template for drafting nomination support. However, members are encouraged to submit scores and comments through their member accounts (this template matches the online form).

Submitting nominations

To ensure proper tracking of nominations, all information and documents must be supplied online.

  • To begin, access your member account
  • After you have logged in to your account, select the “Nominations” tab, then search the nominee database. Links will appear in search results to guide you in the next steps.
  • Your nominee may already be in the ASCI database because the person was previously nominated or because a nomination or support form has been started for this nomination cycle.

Proposers: Proposers are responsible for ensuring that all information provided for the nomination is accurate and complete. A Proposer may grant access to a nominee to edit certain sections of the nomination (see the guide above for details).

In their accounts, Proposers are able to identify those serving as Seconder and General Supporters of the nomination, although supporters need to provide comments via their own member accounts.

ASCI staff sends acknowledgment of submissions by email after they have been reviewed and found to be complete. Proposers can check the status of their submissions (nominations and support forms) online by accessing their member accounts.

Seconder and General Supporters: To draft and complete forms online, select the nominee from search results; or add the requested information about the nominee you are supporting. General Supporters who are not ASCI members may complete the nomination support template and email it to staff@the-asci.org for handling.

Further clarification

  • Age criterion for Active and International nominees. Nominees in these categories must be age 50 or younger as of January 1, 2022.
  • Exceptions to the age criterion cannot be made. Although the ASCI Council understands that a nominee’s progress may have been delayed because of unavoidable or extreme circumstances, the Council has on multiple occasions discussed exceptions and concluded from each discussion that no policy could be implemented fairly and durably.
  • Limit on number of nominations per nominee. The number of nominations per nominee is limited to 3, provided the nominee is age 50 or younger as of January 1, 2022.
  • Limit on number of nominations proposed, seconded, or supported. There is no limit to the number of nominations a member may propose or support (either as Seconder or General Supporter).
  • PhD-only candidates. Active and International nominations are, per the ASCI’s bylaws, restricted to physicians.
  • MD-equivalent candidates are eligible for nomination.
  • Faculty appointment versus nominee’s country of residence. The distinction between Active and International nominations is made on the basis of residence, not faculty appointment. Active nominees must reside in the US or Canada. Candidates residing elsewhere should be nominated in the International category.

Voters approve bylaws amendments regarding membership nominations and other items

A ballot was issued to Active voters on July 12, 2021, that proposed the following changes to the organization’s bylaws:

“Article II – Objectives”: remove outdated description of the Society’s publications, “… for national and international distribution, on subscription at prices not in excess of calculated expenses and needs, …”

“Article III – Membership, Section 2, Membership nomination and election”:

  1. Increase the annual limit for Active and Foreign Associate candidates recommended for election, from 80 to 100.
  2. Re-establish the Honorary membership nomination category as distinct from the Active and Foreign Associate category, with an annual limit of 10 for election via a distinct ballot item.
  3. Allow Foreign Associate members to vote on membership recommendations.
  4. Allow Emeritus and Honorary members to serve as proposers and seconders of membership nominations.

Rename “Foreign Associate” members to “International” throughout the bylaws.

By the July 19, 2021, deadline, 44.7% of eligible voters responded, reaching the minimum 40% participation rate required for ballot items regarding bylaws amendments. For each proposed amendment, the percentage of voters who responded favorably was over the 75% threshold required to approve amendments.

Following the bylaw’s Ballot Review Committee section, these results were received, reviewed, and verified by Priscilla Hsue (2021-2023 ASCI Secretary-Treasurer) and two Active members identified by random selection from ballots submitted and who agreed to audit the results. Thank you to Joseph R. Arron, MD, PhD (Genentech) and Ravi Thadhani, MD, MPH (Mass General Brigham) for their service.

Nominations open for 9th annual Harrington Prize for Innovation in Medicine

Harrington Discovery Institute and the ASCI collaborate to recognize an outstanding achievement of a physician-scientist globally

National and international nominations are being sought for the 2022 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application. 

The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio—part of The Harrington Project for Discovery & Development—and the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected medical honor societies. The Harrington Discovery Institute is a nonprofit institute dedicated to helping physicians and scientists advance promising discoveries into medicines for unmet needs.

Both organizations recognize the challenges associated with translating discoveries into medicines, and they are eager to highlight those who have navigated the path successfully or whose work has led to novel treatments.

A committee composed of members of the Harrington Discovery Institute Scientific Advisory Board and the ASCI Council will review the nominations and select the awardee. In addition to the honorarium, the 2022 recipient will deliver the Harrington Prize Lecture at the 2022 Joint Meeting of the Association of American Physicians (AAP), the ASCI, and the American Physician Scientists Association (APSA); will lecture at the 2022 Harrington Discovery Institute Symposium; and will publish a personal essay in the Journal of Clinical Investigation.

Submitting a Nomination:

  • The deadline for nominations is September 29, 2021 (extended from September 20).
  • Multiple nominations from an institution are welcomed.
  • Teams are accepted for a nomination, but a primary nominee is required.
  • Nomination guidelines can be found at HarringtonDiscovery.org/ThePrize.

Previous Harrington Prize recipients:

  • 2014: Harry Dietz, MD, Johns Hopkins University, for his contributions to the understanding of the biology and treatment of Marfan syndrome, a disorder leading to deadly aneurysms in children and adults.
  • 2015: Douglas R. Lowy, MD, The National Cancer Institute, in recognition of his discoveries that led to the development of the Human Papillomavirus vaccine to prevent cervical cancer.
  • 2016: Jeffrey M. Friedman, MD, PhD, The Rockefeller University, for his discovery of leptin, which controls feeding behavior and is used to treat related clinical disorders.
  • 2017: Jointly awarded to Daniel J. Drucker, MD, Mount Sinai Hospital, Canada, Joel F. Habener, MD, Massachusetts General Hospital, and Jens J. Holst, MD, DMSc, University of Copenhagen, Denmark, for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes.
  • 2018: Helen H. Hobbs, MD, UT Southwestern Medical Center, for the discovery of the link between a gene mutation (PCSK9) and lower levels of LDL, which has improved the treatment of high cholesterol.
  • 2019: Carl H. June, MD, University of Pennsylvania, for advancing the clinical application of CAR T therapy for cancer treatment, and for his sustained contributions to the field of cellular immunology.
  • 2020: Stuart H. Orkin, MD, Harvard University, for breakthrough discoveries on red blood cells that offer new treatments for patients with sickle cell disease and beta-thalassemia, which are among the most common genetic disorders.
  • 2021: Jointly awarded to Warren J. Leonard, MD, NHLBI and John J. O’Shea, MD,  NIAMS, NIH, for their respective contributions to the field of immunology, from fundamental discovery to therapeutic impact.

For questions or more information about the nomination requirements, visit HarringtonDiscovery.org/ThePrize or contact Bronwyn Monroe, Harrington Discovery Institute Program Director, at Bronwyn.Monroe@HarringtonDiscovery.org.

Physician-scientist leaders recognize Dr. Anthony S. Fauci with a Public Service & Courage Award

The Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI) recognize Anthony S. Fauci, MD, with a Public Service & Courage Award.  The foremost purpose of this award is to draw attention to Dr. Fauci’s exemplary contributions and dedication to public health. The award also recognizes Dr. Fauci’s courage in raising his voice for a science-driven approach to public health and safety despite the risk to his personal security.

During his decades-long career as Director of the US National Institute of Allergy and Infectious Diseases (NIAID), Dr. Fauci has overseen a multitude of programs to advance the science and treatment of infections and immune disorders. Of particular note has been his commitment to transparency and honesty in communicating with the public during the ongoing COVID-19 pandemic. Dr. Fauci has strenuously advocated for the health of the nation based on science and data-driven information even as detractors have attempted to impugn his character.

The AAP, founded in 1885, and the ASCI, founded in 1908, represent thousands of physician-scientist leaders across the United States and internationally. Dr. Fauci was elected to the ASCI in 1976 and to the AAP in 1979; served as President of the AAP; and has previously received the AAP’s George M. Kober Medal for his enormous impact in the field of internal medicine and on the many outstanding scientists he has trained.

Additional reading on Dr. Fauci:

  • Gallin JI. 2007 Association of American Physicians George M. Kober Medal: Introduction of Anthony S. Fauci, MD. J Clin Invest. 2007;117(10):3131–3135. https://doi.org/10.1172/JCI33692.
  • Fauci AS. A view from Washington through the eyes of an AAP physician-scientist: 2007 Association of American Physicians George M. Kober Medal. J Clin Invest. 2007;117(10):3136–3139. https://doi.org/10.1172/JCI33691.
  • Neill US. A conversation with Tony Fauci. J Clin Invest. 2014;124(7):2814–2815. https://doi.org/10.1172/JCI77277. [Part of the JCI series “Conversations with Giants in Medicine.”]

New Council members elected, 2021

The ASCI is pleased to announce the results of a recent ballot to fill Council vacancies. Dr. Priscilla Hsue, Secretary-Treasurer Elect, oversaw the ballot; Drs. Sara E. Cosgrove and Ralph J. DeBerardinis volunteered as auditors.

The following members will join the Council at the conclusion of the upcoming AAP/ASCI/APSA Joint Meeting, April 8-10.

Vice President: Benjamin D. Humphreys, MD, PhD

Benjamin D. Humphreys, MD, PhD

Dr. Humphreys is Chief of the Division of Nephrology at Washington University in St. Louis and the Joseph P. Friedman Professor of Renal Diseases in Medicine. His research focuses on the cellular and molecular mechanisms of kidney injury and repair. Elected to the ASCI in 2013, he served as the ASCI’s 2019-2021 Secretary-Treasurer.


Councilor: Julie Anne Bastarache, MD

Julie Anne Bastarache, MD

Dr. Bastarache is a Pulmonary and Critical Care translational physician-scientist at Vanderbilt University Medical Center and the Department of Veterans Affairs. Her research focuses on mechanisms that drive acute lung, brain and kidney injury in sepsis and critical illness. Dr. Bastarache was elected to the ASCI in 2020.


Councilor: Goutham Narla, MD, PhD

Goutham Narla, MD, PhD

Dr. Narla is the Division Chief of Genetic Medicine at the University of Michigan and an Associate Professor of Internal Medicine at Michigan Medicine. His research focuses on the study of the structural and molecular basis for tumor suppressor gene inactivation in cancer initiation, development and progression. Dr. Narla was elected to the ASCI in 2016.


Councilor: Elizabeth K. Speliotes, MD, PhD, MPH

Elizabeth K. Speliotes, MD, PhD, MPH

Dr. Speliotes is the Keith Henley Endowed Professor of Gastroenterology and Computational Medicine and Bioinformatics at the University of Michigan. She conducts large-scale genomic studies of obesity and nonalcoholic fatty liver disease to identify genetic variants that predispose to disease and define disease subtypes. Dr. Speliotes was elected to the ASCI in 2013.

Recipient of the 2021 Seldin~Smith Award for Pioneering Research: Rajan Jain, MD

Dr. Jain

The American Society for Clinical Investigation (ASCI) is pleased to announce Rajan Jain, MD, as the recipient of the 2021 Donald Seldin~Holly Smith Award for Pioneering Research. Dr. Jain will receive an unrestricted award of $30,000 to advance his academic efforts and will deliver a scientific talk at the 2022 AAP/ASCI/APSA Joint Meeting.

Dr. Jain’s work has revolved around understanding and deciphering how cells decide their fate and remember their identity over their lifetime. His program strives to understand the rules governing how DNA is packaged in three-dimensions in the nucleus and the importance of this organization for cellular function in health and disease. Dr. Jain’s work along with that of collaborators has shown that genome interactions with the nuclear periphery via the lamina protein network regulates differentiation of stem cells into cardiac myocytes. As a practicing cardiologist, Dr. Jain has extended his work to understanding cardiomyopathies with genetic etiologies, specifically those with mutations in LAMIN A/C (LMNA). He and colleagues recently showed that pathogenic LMNA variants disrupt three-dimensional genome organization in a tissue-specific fashion. Their work demonstrated that LMNA mutations target specific regions of the genome associated with the nuclear periphery preferentially in cardiac myocytes and result in misexpression of non-muscle genes in mutant cardiac tissues. Taken together, his work underscores a critical role for peripheral genome organization in guarding cellular identity. Dr. Jain has expanded his program’s focus into the mechanisms underlying genome-genome interactions and the implications for understanding progressive lineage restriction. Dr. Jain’s long-term goal is to use this knowledge to develop and/or improve targeted therapies for inherited as well as more common cardiac disorders.

Jonathan A. Epstein, MD, Senior Vice President, Executive Vice Dean, and Chief Scientific Officer, Penn Medicine, who supported Dr. Jain’s nomination, noted that he “is a brilliant and collaborative star who spans disciplines and acts as a connector. I am confident that his ongoing work will reshape our understanding of how gene programs are coordinated to regulate lineage restriction and cellular plasticity.”

Dr. Jain earned his BA from the University of California, Berkeley and his MD from New York University. He subsequently completed his internship and residency in internal medicine at Penn Medicine, where he continued with his clinical fellowship in cardiovascular medicine and research training. He is currently an Assistant Professor of Medicine and Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania. Dr. Jain’s research has been supported in part by the American Heart Association, Allen Foundation, Burroughs Wellcome Foundation, the National Institutes of Health (NHLBI, NIGMS, NIDA, and NIH Director’s High-Risk, High-Reward Program).

Nominations were evaluated by the Seldin~Smith Award Selection Committee: Mukesh K. Jain (Chair), Vivian G. Cheung, Charles L. Sawyers, Elizabeth M. McNally, and W. Kimryn Rathmell. Finalists were evaluated by an Advisory Committee comprising five physician-scientist luminaries: Joseph L. Goldstein (Chair), Michael S. Brown, Robert J. Lefkowitz, Christine Seidman, and Arthur Weiss.

The 2021 Harrington Prize for Innovation in Medicine: Warren J. Leonard, MD, and John J. O’Shea, MD

Dr. Leonard
Dr. Leonard
Dr. O'Shea
Dr. O’Shea

The eighth annual Harrington Prize for Innovation in Medicine is jointly awarded to Warren J. Leonard, MD, NHLBI, NIH Distinguished Investigator, and John J. O’Shea, MD, Scientific Director, NIAMS, NIH, for their respective contributions to the field of immunology, from fundamental discovery to therapeutic impact.

The Harrington Prize for Innovation in Medicine, established in 2014 by the Harrington Discovery Institute at University Hospitals and The American Society for Clinical Investigation (ASCI), honors physician-scientists who have moved science forward with achievements notable for innovation, creativity and potential for clinical application.

Cytokines, small proteins that modulate lymphocyte (immune cell) behavior, play an important role in the body’s immune response. A major group of cytokines termed interleukins (IL) were discovered in the 1970s and over 30 family members have been subsequently identified. The discovery of interleukin-2 (IL-2) as central to regulating T-lymphocyte activity was a major advance in the field. The 2021 Harrington Prize recognizes two physician-scientists whose individual and collaborative work has provided fundamental insights into IL-2-related biology, led to new diagnostics for human immunodeficiency syndromes, and resulted in a new class of therapeutics for numerous inflammatory and autoimmune disorders.

Dr. Leonard’s discovery of the IL-2 receptor was a major advance in the field. His studies also revealed that one component of this receptor, termed the gamma chain (IL-2Rγ), was shared amongst receptors for numerous interleukins, and thus central to signaling within the immune system. Indeed, seminal work by Dr. Leonard in 1993 demonstrated that patients with mutations in IL-2Rγ suffered from the immune disorder X-linked severe combined immunodeficiency (XSCID), or “Bubble Boy” disease. Babies born with XSCID have little to no immune protection, making them prone to developing life-threatening infections. Dr. Leonard’s work has also led to new molecular diagnostics in XSCID and paved the way to gene therapy for human XSCID.

Dr. O’Shea discovered the signaling protein JAK3 and showed that it was essential for the immune actions of interleukins that share IL-2Rγ. In collaborative papers in 1994 and 1995, Drs. Leonard and O’Shea demonstrated that JAK3 signals “downstream” of IL-2Rγ, leading them to predict and then demonstrate that similar to mutations in IL-2Rγ, mutations in JAK3 result in severe combined immunodeficiency. This finding suggested that therapies inhibiting JAK3 activity may dampen the immune system, which is overactive in many diseases. Dr. O’Shea then collaborated with industry to develop an oral JAK inhibitor for rheumatoid arthritis. This work has inspired a new field of JAK inhibitors, referred to as “jakinibs”, which are being evaluated in clinical trials for a wide range of inflammatory and immune diseases.

A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers from four countries before selecting the 2021 Harrington Prize recipients.

“The impact Drs. Leonard and O’Shea have had on the field of immunology is nothing short of extraordinary. Their work spans the full continuum from discovery to bedside and represents precisely the type of advancements the Harrington Prize seeks to recognize,” said Lorraine B. Ware, MD, Professor of Medicine, Vanderbilt University School of Medicine and 2020-2021 President of the ASCI.

“We are pleased to recognize the groundbreaking work of Drs. Leonard and O’Shea. They are exemplary physician-scientists who have moved a field forward and transformed the standard of care. Their work will continue to have therapeutic impact for years to come,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute, Robert S. and Sylvia K. Reitman Family Foundation Distinguished Professor of Cardiovascular Innovation and Professor of Medicine and of Biochemistry at University Hospitals and Case Western Reserve University.

In addition to receiving a $20,000 honorarium, co-recipients Dr. Leonard and Dr. O’Shea will deliver The Harrington Prize Lecture at the 2021 AAP/ASCI/APSA Joint Meeting, will be featured speakers at the 2021 Harrington Scientific Symposium, and will co-publish an essay in the Journal of Clinical Investigation.

Harrington Discovery Institute

The Harrington Discovery Institute at University Hospitals in Cleveland, OH – part of The Harrington Project for Discovery & Development – aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World’.

The Harrington Project for Discovery & Development

The Harrington Project for Discovery & Development (The Harrington Project), founded in late February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational valley of death. It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines. For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.

The 2021 Stanley J. Korsmeyer Award: Benjamin L. Ebert, MD, PhD

Benjamin L. Ebert, MD, PhD, is the recipient of the 2021 Stanley J. Korsmeyer Award from the American Society for Clinical Investigation (ASCI) for his contributions to the understanding of the genetics, biology, and treatment of myeloid malignancies.

Dr. Ebert received a bachelor’s degree from Williams College; a doctorate from Oxford University on a Rhodes Scholarship under the mentorship of Sir Peter Radcliffe; and an MD from Harvard Medical School. He completed a residency in Internal Medicine at Massachusetts General Hospital, a fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute, and a postdoctoral fellowship with Dr. Todd Golub at the Broad Institute.

Dr. Ebert’s laboratory focuses on myelodysplastic syndrome (MDS), a myeloid malignancy that frequently progresses to acute myeloid leukemia. Dr. Ebert initially worked to identify the gene responsible for a type of MDS arising from a specific chromosomal deletion of chromosome 5q. After finding in clinical trials that patients with this deletion had a better response to lenalidomide treatment, his laboratory identified the mechanistic basis for lenalidomide activity in both MDS and multiple myeloma. Lenalidomide induces the targeted degradation of disease-associated proteins. Further research revealed additional mechanisms of targeted protein degradation. These findings have helped open avenues for the identification of novel therapeutics.

In studies to characterize the premalignant state for myeloid malignancies, Dr. Ebert’s laboratory extended knowledge about clonal hematopoiesis, the state arising when a hematopoietic stem cell produces an expanded population of blood cells. His laboratory characterized the genetics of clonal hematopoiesis of indeterminate potential (termed CHIP), a premalignant state that affects more than 10% of people by age 70, and is associated with greater risk of hematologic malignancy, cardiovascular disease, and overall mortality. This knowledge may lead to prediction of disease risk and to improved patient outcomes through earlier detection and treatment of disease.

Dr. Ebert is the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, the Chair of Medical Oncology at the Dana-Farber Cancer Institute, an Institute Member of the Broad Institute, and a Howard Hughes Medical Institute Investigator. Numerous foundations and organizations have supported his work; among these are the William Lawrence & Blanche Hughes Foundation, the Leukemia & Lymphoma Society, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and the Edward P. Evans Foundation. He has received  funding from the National Cancer Institute and the National Heart, Lung, and Blood Institute, among other US federal agencies.

Dr. Ebert’s achievements have been recognized widely. He received the William Dameshek Prize from the American Society of Hematology in 2017, the Meyenburg Prize from the Meyenburg Foundation in 2019, and the Sjöberg Prize from the Sjöberg Foundation and the Royal Swedish Academy of Sciences in 2021. He was elected to the Association of American Physicians in 2015 and the National Academy of Medicine in 2019. Elected to the ASCI in 2011, Dr. Ebert subsequently became an ASCI Council member in 2015 and served as ASCI President, 2017-2018.

Call for applications, JCI Editor, 2022-2027

The American Society for Clinical Investigation (ASCI) invites applications for the position of Editor in Chief of the Journal of Clinical Investigation (JCI). The JCI, one of the oldest and most respected biomedical journals, is renowned for publishing exemplary studies focused on the mechanistic basis and treatment of disease. The ASCI seeks a dynamic Editor in Chief who will lead a team of academic editors to sustain and strengthen the journal in the highly competitive publishing landscape.

Duties of the Editor

The Editor is responsible for: determining the scientific scope and content of the JCI; ensuring the quality and integrity of publications; assembling and leading an Editorial Board to handle research submissions; and meeting goals set by the ASCI Council and Publications Committee.

The selected candidate will serve on the ASCI Council and fulfill the responsibilities of a Council member during their tenure with the JCI. The term of office is 5 years and begins March 2022.

Strategic Focus

The Editor must provide a clear vision for the future scientific development of the JCI, with a particular emphasis on how the journal can expand its portfolio of high-impact research publications, such as clinical trials, translational studies, and cutting-edge genomics and bioinformatics research. The successful applicant should articulate a vision for attracting high-quality submissions to the journal. It is also important to ensure that JCI complements rather than competes with JCI Insight in the ASCI family of journals. The Editor works in collaboration with the Editorial Board, the JCI Executive Editor, the ASCI publishing staff, and the ASCI Publications Committee to set priorities for the journal.

Eligibility of the Editor and Editorial Board

To be considered for the position of Editor, a candidate must:

  • be a member of the ASCI
  • demonstrate a strong scientific record

For the proposed Editorial Board:

  • At least two-thirds must be ASCI members (Active or Senior) in good standing
  • Multi-institution applications are encouraged

Application timeline

  • May 17, 2021 (extended from May 3, 2021): Letters of intent (LOI) due. The LOI only needs to include the name of the proposed Editor in Chief and their affiliated institution but does not need to specify details regarding the application. Applicants submitting LOI will receive an operational overview of the ASCI and JCI for use in developing full applications.
  • August 2, 2021: Full applications due.
  • September 20, 2021: Finalists for the Editor position determined.
  • October 15 and October 18, 2021: Editor Selection Committee interviews finalists

Full application requirements

The applicant should address the following areas in 5 or fewer single-spaced pages:

  • Describe your vision for the scientific scope of manuscripts published in the journal under your leadership, including scientific areas you see as priorities for the JCI, potential new article categories (if applicable), and areas you see as opportunities for growth and increased impact.
  • Provide details regarding proposed Editorial Board members.
    • Describe how you will ensure that the team has the breadth to handle submissions across all specialties, including any areas of new or expanded emphasis for the journal.
    • Describe how Clinical Medicine submissions will be encouraged and handled, including any Board members with specific expertise in clinical research and translational medicine. Clinical research expertise among the Editorial Board leadership is strongly encouraged.
    • Specify Board members with expertise in -omics and bioinformatics, and any efforts that will be made to expand submissions in these areas
  • Describe how the proposed Board will evaluate manuscripts and specific efforts to ensure scientific rigor, fair decisions, and timeliness.
  • Describe your vision for attracting the best research submissions to the journal.
  • In the event that you cannot complete the duration of the term, describe the process by which a candidate to replace the Editor in Chief would be identified (subject to approval by the Council and a vote by the membership).

In addition, the application must include a letter from each proposed Board member stating a commitment to the role.

Submitting letters of intent and applications

Address materials to Sohail F. Tavazoie, MD, PhD, Chair, Editor Selection Committee, and send as an attachment to staff@the-asci.org.

Questions

Contact Sarah Jackson, Executive Editor, at sarah.jackson@the-jci.org.

Review of applications

The Editor Selection Committee will review applications, interview candidates, and recommend a candidate to the ASCI Council, which then submits the recommendation to a vote of the Active segment of the ASCI membership.

Editor Selection Committee

Chair

Sohail F. Tavazoie, MD, PhD
The Rockefeller University

Members

Rexford S. Ahima, MD, PhD
Johns Hopkins University School of Medicine

Kathleen L. Collins, MD, PhD
University of Michigan Medical School

Jennifer Rubin Grandis, MD, FACS
University of California, San Francisco, School of Medicine

Priscilla Hsue, MD
University of California, San Francisco, School of Medicine

Benjamin D. Humphreys, MD, PhD
Washington University School of Medicine in St. Louis

Martin G. Myers, Jr., MD, PhD
University of Michigan Medical School

M. Bishr Omary, MD, PhD
Rutgers, Robert Wood Johnson Medical School

Robert H. Vonderheide, MD, DPhil
University of Pennsylvania Perelman School of Medicine

Non-voting member

Sarah C. Jackson, PhD
Executive Editor, American Society for Clinical Investigation

New members, 2021

The ASCI is pleased to announce the election of the Society’s new members for 2021.

These new members come from 43 different institutions and represent excellence across the breadth of academic medicine. They will be officially inducted into the Society on April 8, 2021, as part of the 2021 AAP/ASCI/APSA Joint Meeting, held virtually April 8-10.

The Council recommended 80 nominees (the limit according to the ASCI bylaws) for election from the 245 nominations submitted for consideration. The Active and Senior segments of the membership voted on the recommendation, with 41% of eligible voters submitting their ballots by the deadline. The vote was overwhelmingly in favor of approving the recommendation.

Benjamin Humphreys, the 2019-2021 Secretary-Treasurer, oversaw and served as one of three required auditors of the ballot, as per the bylaws. Drs. Kenneth J. Mukamal and Martin G. Myers volunteered to serve as the other two auditors who reviewed and confirmed the results.

NomineeInstitution
Muktar Hassan Aliyu, MBBS, MPH, DrPHVanderbilt University School of Medicine
Daniel Evan Bauer, MD, PhDHarvard Medical School, Boston Children’s Hospital
Himisha Beltran, MDHarvard Medical School, Dana-Farber Cancer Institute
Ami S. Bhatt, MD, PhDStanford University School of Medicine
Cynthia Melinda Boyd, MD, MPHJohns Hopkins University School of Medicine
Supinda Bunyavanich, MD, MPH, M.PhilIcahn School of Medicine at Mount Sinai
Mark Edward Burkard, MD, PhDUniversity of Wisconsin School of Medicine and Public Health
Martin D. Burke, MD, PhDUniversity of Illinois at Urbana-Champaign
Manish J. Butte, MD, PhDUniversity of California, Los Angeles, David Geffen School of Medicine
Lauren Averett Byers, MD, MSUniversity of Texas MD Anderson Cancer Center
Julie P.W. Bynum, MD, MPHUniversity of Michigan Medical School
Kirk Campbell, MDIcahn School of Medicine at Mount Sinai
Susan Cheng, MD, MPH, MMScCedars-Sinai Medical Center
Jaehyuk Choi, MD, PhDNorthwestern University Feinberg School of Medicine
Sung Won Choi, MDUniversity of Michigan Medical School
Paul Cohen, MD, PhDThe Rockefeller University
Michael Cohen-Wolkowiez, MD, PhDDuke University School of Medicine
Joseph N. Contessa, MD, PhDYale School of Medicine
Patricia I. Dickson, MDWashington University School of Medicine in St. Louis
Nataki C. Douglas, MD, PhDRutgers, New Jersey Medical School
Brian T. Edelson, MD, PhDWashington University School of Medicine in St. Louis
Peter Edward Fecci, MD, PhDDuke University School of Medicine
Jennifer Elizabeth Flythe, MD, MPHUniversity of North Carolina School of Medicine
Stephen J. Freedland, MDCedars-Sinai Medical Center
Walid F. Gellad, MD, MPHUniversity of Pittsburgh Medical Center
Jeffrey Stephen Gerber, MD, PhD, MSCEChildren’s Hospital of Philadelphia
Peyman Golshani, MD, PhDUniversity of California, Los Angeles, David Geffen School of Medicine
Matthew Blake Greenblatt, MD, PhDWeill Cornell Medical College
Alejandro Gutierrez, MDHarvard Medical School, Boston Children’s Hospital
Nadia Nathalie Hansel, MD, MPHJohns Hopkins University School of Medicine
Tara O. Henderson, MD, MPHUniversity of Chicago Pritzker School of Medicine
Mark A. Herman, MDDuke University School of Medicine
Jacqueline Ho, MDUniversity of Pittsburgh Children’s Hospital
Anupam B. Jena, MD, PhDHarvard Medical School
Peng Ji, MD, PhDNorthwestern University Feinberg School of Medicine
Petros C. Karakousis, MDJohns Hopkins University School of Medicine
Purna C. Kashyap, MBBSMayo Clinic
Anna Kottgen, MD, MPHUniversity Medical Center Freiburg
Andrew A. Lane, MD, PhDHarvard Medical School, Dana-Farber Cancer Institute
Benjamin Levi, MDUniversity of Texas Southwestern Medical Center
Deborah A. Levine, MD, MPHUniversity of Michigan Medical School
Philana Ling Lin, MD, MScUniversity of Pittsburgh School of Medicine
Piro Lito, MD, PhDMemorial Sloan Kettering Cancer Center
Carey Nien-Kai Lumeng, MD, PhDUniversity of Michigan Medical School
Tippi Cicek MacKenzie, MDUniversity of California, San Francisco, School of Medicine
Bradley A. Maron, MDHarvard Medical School, Brigham & Women’s Hospital
Nuala J. Meyer, MD, MSUniversity of Pennsylvania Perelman School of Medicine
Constantine S. Mitsiades, MD, PhDHarvard Medical School, Dana-Farber Cancer Institute
Erik Steven Musiek, MD, PhDWashington University School of Medicine in St. Louis
Peggy Suejin Myung, MD, PhDYale School of Medicine
Kristen Jane Nadeau, MS, MD, FAAPUniversity of Colorado School of Medicine
Utpal Pajvani Bhagirath, MD, PhDColumbia University College of Physicians & Surgeons
Ganesh S. Palapattu, MD, FACSUniversity of Michigan Medical School
Christopher Yongchul Park, MD, PhDNew York University School of Medicine
Mitesh S. Patel, MD, MSUniversity of Pennsylvania Perelman School of Medicine
Chad Victor Pecot, MDUniversity of North Carolina School of Medicine
Jennifer A. Philips, MD, PhDWashington University School of Medicine in St. Louis
Christopher Pittenger, MD, PhDYale School of Medicine
Jalees Rehman, MDUniversity of Illinois College of Medicine
Eugene P. Rhee, MD MAHarvard Medical School, Massachusetts General Hospital
Nasia Safdar, MD, PhDUniversity of Wisconsin School of Medicine and Public Health
Jacob G. Scott, MD, DPhilCleveland Clinic
Michael U. Shiloh, MD, PhDUniversity of Texas Southwestern Medical Center
Heath Devin Skinner, MD, PhDUniversity of Pittsburgh Medical Center
Joanna E. Steinglass, MDColumbia University College of Physicians & Surgeons
Matthew L. Steinhauser, MDUniversity of Pittsburgh School of Medicine
Nathan O. Stitziel, MD, PhDWashington University School of Medicine in St. Louis
Sunil Sudarshan, MDUniversity of Alabama at Birmingham School of Medicine
Takanori Takebe, MD, PhDCincinnati Children’s Hospital
Hilary Aurora Tindle, MD, MPHVanderbilt University School of Medicine
Carlo Giovanni Traverso, MB, BChir, PhDHarvard Medical School, Brigham & Women’s Hospital
Chinmay Trivedi, MD, PhDUniversity of Massachusetts Medical School
Alexander C. Tsai, MD, PhDHarvard Medical School, Massachusetts General Hospital
Jeremy Veenstra-VanderWeele, MDColumbia University College of Physicians & Surgeons
Jiou Wang, MD, PhDJohns Hopkins Medical Institutes
Jinoos Yazdany, MD, MPHUniversity of California, San Francisco, School of Medicine
Lisa R. Young, MDChildren’s Hospital of Philadelphia
Xu Yu, MDHarvard Medical School, Massachusetts General Hospital
Lei Zheng, MD, PhDJohns Hopkins University School of Medicine
Julie Zikherman, MDUniversity of California, San Francisco, School of Medicine